ClinicalTrials.gg
CompletedNCT03818035GUIDEUpdated Jan 23, 2026Results posted

A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis

A Phase 3 interventional study of Guselkumab and Placebo Injection in Psoriasis, sponsored by Janssen-Cilag International NV. Completed at 90 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Janssen-Cilag International NV (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
880
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.

Enrollment
3rd of 29
880 · median 120
Started
2019
with 1 other
Phase 3
12 of 29
none open now
Registered
14th of 29
by date

Among the 29 studies testing guselkumab in Psoriasis, this one is the 3rd largest by enrollment, is one of 2 that started in 2019, is one of 12 in phase 3, and was the 14th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing guselkumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate that Super-Responders (SRe; defined as psoriasis participants who receive on-label guselkumab treatment until week 20 and respond with a Psoriasis Area and Severity Index score (PASI) = 0 at weeks 20 and 28) maintain control of disease until week 68 with prolonged treatment intervals of 16 weeks (guselkumab 100 mg every 16 weeks).

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a disease duration of plaque psoriasis of either less than or equal to (\<=2) years or (greater than (>2) years calculated from date at which first symptoms [plaque] were reported by subject to date of screening visit at screening; approximately 40 percentage (%) of participants must have a disease duration \<=2 years
  • Has moderate-to-severe plaque-psoriasis defined by a Psoriasis Area and Severity Index (PASI) score >10 or affected body surface area (BSA) >10%) and additionally a Dermatology Life Quality Index (DLQI) score >10 at baseline (week 0)
  • Have no signs or symptoms suggestive of active tuberculosis (TB) upon medical history and/or physical examination
  • Agrees not to receive a live virus or live bacterial vaccination during the study, or within 3 months after the last administration of study drug
  • Agrees not to receive a Bacille Calmette-Guerin (BCG) vaccination during the study, or within 12 months after the last administration of study drug

Exclusion criteria

Exclusion Criteria:

  • Has previously received any therapeutic agent directly targeted to interleukin (IL) -23 (including but not limited to guselkumab, tildrakizumab [MK3222], risankizumab [BI-655066])
  • Has received any systemic (for example, methotrexate, azathioprine, cyclosporine, 6-thioguanine, mercaptopurine, mycophenolate mofetil, tacrolimus, fumaric acid esters), or anakinra within 4 weeks of the first administration of study drug.
  • Tests positive for virus (HBV) infection or who are seropositive for antibodies to virus (HCV), unless they have 2 negative HCV RNA test results 6 months apart after completing antiviral treatment and prior to baseline and have a third negative HCV RNA test result at baseline
  • Has received natalizumab, belimumab, or agents that modulate B cells or T cells (e.g., rituximab, alemtuzumab, abatacept, or visilizumab) within 12 months of the first administration of study drug
  • Has received any anti - tumor necrosis factor (TNF)-α biologic therapy within 3 months before the first administration of study drug
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
880 participants (actual)

Study arms

  • Experimental
    Part 1: Guselkumab

    Participants in group 1 (Part 1) will receive 100 milligram (mg) guselkumab subcutaneously (SC) at Weeks 0, 4, 12 and 20.

    Drug: Guselkumab

  • Experimental
    Part 2: Guselkumab q8w and Guselkumab q16w

    Eligible participants from Part 1 will continue to participate in Part 2. Participants (super responder \[SRe\]) with a Psoriasis Area and Severity Index (PASI) score = 0 at weeks 20 and 28 will be randomized to guselkumab 100 mg every 8 weeks (q8w) (group 2a) or guselkumab 100 mg q16w (group 2b), at weeks 28 to 60. Group 2b will receive placebo injection at weeks 28, 44 and 60 to keep the comparison double blind. Participants losing control of disease (PASI score \>5) during study Part 2 (until week 60), will enter the re-treatment arm (group 2d) and receive guselkumab 100mg q8w (at re-treatment week 0), followed by administration at re-treatment-weeks 8 and 16.

    Drug: Guselkumab

  • Experimental
    Part 2: Guselkumab q8w

    Participants (Non SRe) in group 2c with a PASI score greater than (\>) 0 at week 20 and/or 28 will continue to receive guselkumab 100 mg q8w until week 60.

    Drug: Guselkumab · Drug: Placebo Injection

  • Experimental
    Part 3: Guselkumab Withdrawal

    Participants from groups 2a and 2b with a PASI score \<3 at week 68 will be included in Part 3 (group 3a and 3b) and be withdrawn from guselkumab. Study visits will be conducted every 12 weeks until week 220 (follow-up). Participants with fluctuating disease (PASI score greater than or equal to \[\>=\] 3) at week 68 or PASI \>5 (participants losing control of disease) at any visit during part 3 after week 68 will get an opportunity to enter the re-treatment-arm (group 3c) in which participants will receive three guselkumab injections of 100 mg q8w.

    Drug: Guselkumab

Interventions

  • Participants will receive 100 mg guselkumab subcutaneously at Weeks 0, 4, 12 and 20 (group 1), at weeks 28, 36, 44, 52, 60 (group 2a and 2c), and at weeks 36 and 52 (group 2b). Group 2d and 3c are the re-treatment groups and will receive three injections after loss of disease control.

    Also known as: TREMFYA

  • DrugPlacebo Injection

    Participants of group 2b will receive matching placebo injection subcutaneously at weeks 28, 44 and 60.

06

What researchers measure

Primary outcomes

  1. Group 2a and Group 2b: Percentage of Participants Who Achieved an Absolute Psoriasis Area and Severity Index (PASI) Score Less Than (<) 3 at Week 68

    Percentage of participants who achieved an absolute PASI \<3 at Week 68 were reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the body surface area involved, which translates to a numeric score that ranged from 0 (indicated no involvement) to 6 (90 percent \[%\]-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis.

    Time frame: Week 68

Secondary outcomes

  1. Groups 1 and 2c: Time to Improvement From Baseline (Week 0) in PASI Score

    Time to improvement from baseline in PASI 75/90/100 response for participants with short disease duration (SDD) and longer disease duration (LDD) was reported. PASI was used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to numeric score that ranged from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced numeric score ranging from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. PASI responders were participants with \>=75%, \>=90%, 100% improvement in PASI respectively. For Part 2, data is reported only for those groups in which participants had PASI improvement post Week 28.

    Time frame: Group 1: Week 0 up to Week 28; Group 2c: Week 28 up to Week 68

  2. Groups 1, 2a, 2b, 2c, 3a and 3b: Percentage of Participants With Short (<=2 Years) and Longer (>2 Years) Disease Duration Who Achieved an Absolute PASI Score of 0, <=1 and <3 at Weeks 20, 28, 68, 116, 164 and 220

    Percentage of participants with short (\<=2 years) and longer (\>2 years) disease duration who achieved an absolute PASI Score of 0, \<=1 and less than (\<) 3 was reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.

    Time frame: Group 1: Weeks 20 and 28; Groups 2a, 2b, 2c: Week 68; Groups 3a and 3b: Weeks 116, 164 and 220

  3. Group 3a and Group 3b: Percentage of Participants With Short (<=2 Years) and Longer (>2 Years) Disease Duration Who Retain Disease Control (Absolute PASI Score < 3)

    Percentage of participants who retain disease control (that is, absolute PASI score \<3 from Week 68 through Week 220 for participants with short (\<= 2 years) and longer (\>2 years) disease duration was reported. Control of disease was defined as participants with a PASI score \<3. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease

    Time frame: From Week 68 up to Week 220

  4. Groups 1, 2a, 2b, 2c, 3a and 3b: Percentage of Participants Who Achieved a PASI 75/90/100 Response at Weeks 20, 28, 68, 116, 164, and 220

    Percentage of participants who achieved PASI 75/90/100 response were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. PASI 75 responders were defined as participants with \>= 75% improvement in PASI from baseline. PASI 90 responders were defined as participants with \>= 90% improvement in PASI from baseline. PASI 100 responders were defined as participants with 100% improvement in PASI from baseline.

    Time frame: Group 1: Weeks 20, 28; Groups 2a, 2b, 2c: Week 68; Groups 3a, 3b: Weeks 116, 164 and 220

  5. Group 3a and Group 3b: Time to Loss of Disease Control (Absolute PASI Score >5) After Treatment Withdrawal

    Time to loss of disease control (absolute PASI score \>5) after treatment withdrawal beyond Week 68 up to Week 220 were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.

    Time frame: From Week 68 up to Week 220

  6. Group 1: Percentage of Participants With an Absolute PASI Score = 0 at Weeks 12, 16, 20 and 28

    Percentage of participants with an absolute PASI score = 0 at Weeks 12, 16, 20 and 28 were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.

    Time frame: Weeks 12, 16, 20 and 28

  7. Groups 1, 2a, 2b, 2c, 3a, 3b and 3c: Change From Baseline (Week 0) in Dermatology Life Quality Index (DLQI) Score

    Change from baseline (Week 0) in DLQI score were reported. DLQI was a 10-item instrument questionnaire designed to assess the impact of the disease on a participant's quality of life. Each question was evaluated on a 4-point scale ranged from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.

    Time frame: Group 1: Baseline (Week 0), Week 28; Group 2a, 2b, 2c: Baseline (Week 0), Week 68; Group 3a and Group 3b:Baseline (Week 0), Week 116, 164 and 220; Group 3c: Baseline (Re-Treatment [R] Week 0), Week R24

  8. Groups 1, 2a, 2b, 2c, 3a, 3b and 3c: Percentage of Participants Who Achieved a DLQI Score 0/1 and <5

    Percentage of participants who achieved a DLQI score 0/1 and \<5 was reported. DLQI was a 10-item instrument questionnaire designed to assess the impact of the disease on a participant's quality of life. Each question was evaluated on a 4-point scale ranged from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.

    Time frame: Group 1: Week 28; Groups 2a, 2b, 2c: Week 68; Groups 3a and 3b: Week 116, 164 and 220; Group 3c: Week R24

  9. Groups 1, 2a, 2b, 2c, 3a, and 3b: Percent Change From Baseline (Week 0) in Psoriasis- Affected Body Surface Area (BSA)

    Percent change from baseline in the psoriasis affected BSA (%) was reported. The percentage of the psoriasis-affected BSA percentage is a system used for assessing the severity of psoriasis. The plaque coverage is estimated using the rule of palm (1 palm of the hand = 1% BSA)

    Time frame: Group 1: Baseline (Week 0), Week 12, 28; Group 2a, 2b, 2c: Baseline (Week 0), Week 52 and 68, Group 3a, 3b: Baseline (Week 0), Week 80, 104, 116, 140, 164, 188, 212 and 220

  10. Groups 1, 2a, 2b, 2c, 3a and 3b: Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis- Clinical (NAPPA-CLIN) at Weeks 28, 68, 116, 164 and 220

    Change from baseline in NAPPA-CLIN at Weeks 28, 68, 116 164, and 220 was reported. NAPPA-CLIN is an instrument used by the physician to assess the least and the worst involved nail of both hands or both feet with scores ranging from 0 (no involvement) to 16 (worst involvement). A higher score indicated a worst involvement.

    Time frame: Group 1: Baseline (Week 0), Week 28; Group 2a, 2b, 2c: Baseline (Week 0), Week 68; Group 3a and Group 3b: Baseline (Week 0), Week 116, 164, and 220

  11. Groups 1, 2a, 2b, 2c, 3a and 3b: Change From Baseline (Week 0) in the Signs and Symptoms Aggregate Scores of the Psoriasis Symptoms and Signs Diary (PSSD) at Weeks 28, 68, 116, 164 and 220

    Change from baseline (Week 0) in the signs and symptoms aggregate scores of the PSSD at Weeks 28, 68, 116, 164 and 220 was reported. The PSSD was a questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a participant self-administered outcomes instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores each ranging from 0 to 100 were derived: the psoriasis symptom score and the psoriasis sign score. A higher score indicated more severe disease. A change of \>= 40 points in PSSD symptom score or sign score, and a \>= 3-point change in individual PSSD item scale scores was defined as clinically meaningful change (response).

    Time frame: Group 1: Baseline (Week 0), Week 28; Group 2a, 2b, 2c: Baseline (Week 0), Week 68; Group 3a and Group 3b: Baseline (Week 0), Week 116, 164, and 220

  12. Groups 2a, 2b and 2c: Percentage of Participants Who Achieved a PSSD Sign Score = 0 at Week 68 in Participants With a PSSD Sign Score >= 1 at Week 28

    Percentage of participants who achieved a PSSD sign score = 0 at Week 68 in participants with a PSSD sign score \>= 1 at Week 28 was reported. The PSSD was a questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a participant self-administered outcomes instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores each ranging from 0 to 100 were derived: the psoriasis symptom score and the psoriasis sign score. A higher score indicated more severe disease.

    Time frame: Week 68

  13. Groups 2a and 2b: Serum Trough Guselkumab Levels at Weeks 20, 28, 36 and 68

    Serum trough guselkumab levels at Weeks 20, 28, 36 were analyzed. Serum samples were analyzed to determine trough concentrations of guselkumab using a validated specific, and sensitive method. Week 28 data are presented in Part 2 arms (Groups 2a and 2b) as these groups were established at Week 28, however pre-Week 28 trough concentrations are also reported under these groups to assess potential differences between Part 1 PK characteristics.

    Time frame: At Weeks 20, 28, 36, 68

  14. Groups 2d and 3c: Percentage of Participants Who Were Re-Treated Due to Loss of Disease Control (PASI >5) and Regain Control of Disease (PASI <3) 24 Weeks After Start of Re-Treatment

    Percentage of participants who were re-treated due to loss of disease control (PASI \>5) and regain control of disease (PASI \<3) 24 weeks after start of re-treatment was reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to numeric score that ranged from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.

    Time frame: Week R0 up to Week R24

  15. Groups 1, 2a, 2b, 2c, 2d,3a, 3b, and 3c: Percentage of Participants With Adverse Events as a Measure of Safety and Tolerability

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

    Time frame: Group 1: From Week 0 to Week 28; Group 2a,2b 2c: From Week 28 to Week 68; Group 3a, 3b: From Week 68 to Week 220; Group 2d, 3c: From Week R0 to Week R28

  16. Groups 1, 2a, 2b, 2c, 2d, 3a,3b and 3c: Number of Participants With Clinically Significant Laboratory Abnormalities

    Number of participants with clinically significant laboratory abnormalities was reported. Data of participants with at least one lab abnormality is reported. Abnormality criteria: Aspartate Aminotransferase (AST) \>3, Alanine Aminotransferase (ALT).\>5. For arm 3a and 3b, no drug was administered, hence no laboratory data was collected, per planned analysis.

    Time frame: Group 1: Week 20, Group 2a, 2b,2c: Week 68 and Group 2d and 3c: Week R28

07

Results

Posted May 10, 2023
Limitations and caveats
There was an interruption of enrollment due to Corona Pandemic.

Participant flow

Part 1: Open-label (Week 0 to Week 8)
Participant flow — Part 1: Open-label (Week 0 to Week 8)
MilestonePart 1 Group 1: Guselkumab 100mgPart 2 Group 2a: Guselkumab 100 mg Q8WPart 2 Group 2b: Guselkumab 100 mg Q16WPart 2 Group 2c: Guselkumab 100 mg Q8WPart 2 Group 2d: Re-Treatment Guselkumab 100mgPart 3 Group 3a: Withdrawal (Q8W)Part 3 Group 3b: Withdrawal (Q16W)Part 3 Group 3c: Re-Treatment Guselkumab 100mg
Started8800000000
Completed8220000000
Not completed580000000
Withdrew: Lack of efficacy30000000
Withdrew: Lost to follow-up100000000
Withdrew: Protocol violation110000000
Withdrew: Withdrawal by subject80000000
Withdrew: Adverse event - worsening of psoriasis10000000
Withdrew: Adverse event - other160000000
Withdrew: Non-compliance with study drug10000000
Withdrew: Other70000000
Withdrew: Death10000000
Part 2: Double-blind (Week28 to Week68)
Participant flow — Part 2: Double-blind (Week28 to Week68)
MilestonePart 1 Group 1: Guselkumab 100mgPart 2 Group 2a: Guselkumab 100 mg Q8WPart 2 Group 2b: Guselkumab 100 mg Q16WPart 2 Group 2c: Guselkumab 100 mg Q8WPart 2 Group 2d: Re-Treatment Guselkumab 100mgPart 3 Group 3a: Withdrawal (Q8W)Part 3 Group 3b: Withdrawal (Q16W)Part 3 Group 3c: Re-Treatment Guselkumab 100mg
Started01481505250000
Treated01481495250000
Completed01371424960000
Not completed0118290000
Withdrew: Lack of efficacy00040000
Withdrew: Lost to follow-up06190000
Withdrew: Withdrawal by subject00080000
Withdrew: Other adverse events03460000
Withdrew: Adverse event, serious fatal00010000
Withdrew: Participants started retreatment phase within study part 2 before week 6801200000
Withdrew: Other01110000
Part3: Withdrawal (Week 68 to Week 220)
Participant flow — Part3: Withdrawal (Week 68 to Week 220)
MilestonePart 1 Group 1: Guselkumab 100mgPart 2 Group 2a: Guselkumab 100 mg Q8WPart 2 Group 2b: Guselkumab 100 mg Q16WPart 2 Group 2c: Guselkumab 100 mg Q8WPart 2 Group 2d: Re-Treatment Guselkumab 100mgPart 3 Group 3a: Withdrawal (Q8W)Part 3 Group 3b: Withdrawal (Q16W)Part 3 Group 3c: Re-Treatment Guselkumab 100mg
Started000001361370
Completed00000760
Not completed000001291310
Withdrew: Lost to follow-up00000050
Withdrew: Withdrawal by subject00000930
Withdrew: Other adverse events00000020
Withdrew: Non-compliance with study drug00000300
Withdrew: Not signed icf00000540
Withdrew: Other00000020
Withdrew: Retreatment started000001121150
Re-treatment (Week R0 Through Week R28)
Participant flow — Re-treatment (Week R0 Through Week R28)
MilestonePart 1 Group 1: Guselkumab 100mgPart 2 Group 2a: Guselkumab 100 mg Q8WPart 2 Group 2b: Guselkumab 100 mg Q16WPart 2 Group 2c: Guselkumab 100 mg Q8WPart 2 Group 2d: Re-Treatment Guselkumab 100mgPart 3 Group 3a: Withdrawal (Q8W)Part 3 Group 3b: Withdrawal (Q16W)Part 3 Group 3c: Re-Treatment Guselkumab 100mg
Started0000900227
Completed0000900219
Not completed00000008
Withdrew: Lost to follow-up00000003
Withdrew: Withdrawal by subject00000001
Withdrew: Other adverse events00000001
Withdrew: Other00000003

Outcome measures

PrimaryGroup 2a and Group 2b: Percentage of Participants Who Achieved an Absolute Psoriasis Area and Severity Index (PASI) Score Less Than (<) 3 at Week 68

Percentage of participants who achieved an absolute PASI \<3 at Week 68 were reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the body surface area involved, which translates to a numeric score that ranged from 0 (indicated no involvement) to 6 (90 percent \[%\]-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated greater severity of psoriasis.

Time frame:
Week 68
Reported as:
Number · Percentage of participants
Group 2a and Group 2b: Percentage of Participants Who Achieved an Absolute Psoriasis Area and Severity Index (PASI) Score Less Than (<) 3 at Week 68
Percentage of participantsPart 2 Group 2a: Guselkumab 100 mg Q8WPart 2 Group 2b: Guselkumab 100 mg Q16W
Group 2a and Group 2b: Percentage of Participants Who Achieved an Absolute Psoriasis Area and Severity Index (PASI) Score Less Than (<) 3 at Week 6892.6 (88.0 to 95.8)91.9 (87.3 to 95.3)
Statistical analysis
  • Part 2 Group 2a: Guselkumab 100 mg Q8W vs Part 2 Group 2b: Guselkumab 100 mg Q16W · Wald Z-test · p = 0.0013 · Risk difference (rd): -0.6 · 90% CI -5.7 to 4.5
SecondaryGroups 1 and 2c: Time to Improvement From Baseline (Week 0) in PASI Score

Time to improvement from baseline in PASI 75/90/100 response for participants with short disease duration (SDD) and longer disease duration (LDD) was reported. PASI was used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to numeric score that ranged from 0 (no involvement) to 6 (90-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced numeric score ranging from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. PASI responders were participants with \>=75%, \>=90%, 100% improvement in PASI respectively. For Part 2, data is reported only for those groups in which participants had PASI improvement post Week 28.

Time frame:
Group 1: Week 0 up to Week 28; Group 2c: Week 28 up to Week 68
Reported as:
Median · Days
Groups 1 and 2c: Time to Improvement From Baseline (Week 0) in PASI Score
DaysPart 1 Group 1: Participants With Disease Duration <= 2 YearsPart 1 Group 1: Participants With Disease Duration > 2 YearsPart 2 Group 2c: Participants With Disease Duration <= 2 YearsPart 2 Group 2c: Participants With Duration > 2 Years
PASI 7584.0 (81.0 to 89.0)84.0 (81.0 to 90.0)84.0 (83.0 to 112.0)84.0 (83.0 to 105.0)
PASI 9089.0 (84.0 to 134.0)106.0 (84.0 to 140.0)112.0 (84.0 to 153.0)114.0 (84.0 to 196.0)
PASI 100141.0 (105.0 to 210.0)200.0 (113.0 to NA)308.0 (196.0 to 483.0)416.0 (198 to NA)
SecondaryGroups 1, 2a, 2b, 2c, 3a and 3b: Percentage of Participants With Short (<=2 Years) and Longer (>2 Years) Disease Duration Who Achieved an Absolute PASI Score of 0, <=1 and <3 at Weeks 20, 28, 68, 116, 164 and 220

Percentage of participants with short (\<=2 years) and longer (\>2 years) disease duration who achieved an absolute PASI Score of 0, \<=1 and less than (\<) 3 was reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.

Time frame:
Group 1: Weeks 20 and 28; Groups 2a, 2b, 2c: Week 68; Groups 3a and 3b: Weeks 116, 164 and 220
Reported as:
Number · Percentage of participants
Groups 1, 2a, 2b, 2c, 3a and 3b: Percentage of Participants With Short (<=2 Years) and Longer (>2 Years) Disease Duration Who Achieved an Absolute PASI Score of 0, <=1 and <3 at Weeks 20, 28, 68, 116, 164 and 220
Percentage of participantsPart 1 Group 1: Participants With Disease Duration <= 2 YearsPart 1 Group 1: Participants With Disease Duration > 2 YearsPart 2 Group 2a: Participants With Disease Duration <= 2 YearsPart 2 Group 2a: Participants With Disease Duration > 2 YearsPart 2 Group 2b: Participants With Disease Duration <= 2 YearsPart 2 Group 2b: Participants With Disease Duration > 2 YearsPart 2 Group 2c: Participants With Disease Duration <= 2 YearsPart 2 Group 2c: Participants With Disease Duration > 2 YearsPart 3 Group 3a: Participants With Disease Duration <=2 YearsPart 3 Group 3a: Participants With Disease Duration> 2 YearsPart 3 Group 3b: Participants With Disease Duration <= 2 YearsPart 3 Group 3b: Participants With Disease Duration > 2 Years
PASI = 0 (Week 20)49.332.7——————————
PASI <=1 (Week 20)67.854.3——————————
PASI <3 (Week 20)85.282.4——————————
PASI = 0 ( Week 28)51.839.4——————————
PASI <=1 (Week 28)70.359.5——————————
PASI <3 (Week 28)86.883.9——————————
PASI = 0 (Week 68)——81.380.873.764.439.937.2————
PASI <=1 (Week 68)——86.793.281.676.773.655.9————
PASI <3 (Week 68)——90.794.593.490.488.879.8————
PASI = 0 (Week 116)————————14.94.312.71.5
PASI <=1 (Week 116)————————25.45.818.33.0
PASI <3 (Week 116)————————34.311.626.810.6
PASI = 0 (Week 164)————————10.41.45.60.0
PASI <=1 (Week 164)————————13.41.47.00.0
PASI <3 (Week 164)————————14.92.912.73.0
PASI = 0 (Week 220)————————9.005.60
PASI <=1 (Week 220)————————9.005.60
PASI <3 (Week 220)————————10.407.01.5
SecondaryGroup 3a and Group 3b: Percentage of Participants With Short (<=2 Years) and Longer (>2 Years) Disease Duration Who Retain Disease Control (Absolute PASI Score < 3)

Percentage of participants who retain disease control (that is, absolute PASI score \<3 from Week 68 through Week 220 for participants with short (\<= 2 years) and longer (\>2 years) disease duration was reported. Control of disease was defined as participants with a PASI score \<3. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease

Time frame:
From Week 68 up to Week 220
Reported as:
Number · Percentage of participants
Group 3a and Group 3b: Percentage of Participants With Short (<=2 Years) and Longer (>2 Years) Disease Duration Who Retain Disease Control (Absolute PASI Score < 3)
Percentage of participantsPart 3 Group 3a: Participants With Disease Duration <=2 YearsPart 3 Group 3a: Participants With Disease Duration> 2 YearsPart 3 Group 3b: Participants With Disease Duration <= 2 YearsPart 3 Group 3b: Participants With Disease Duration > 2 Years
Group 3a and Group 3b: Percentage of Participants With Short (<=2 Years) and Longer (>2 Years) Disease Duration Who Retain Disease Control (Absolute PASI Score < 3)7.5 (2.5 to 16.6)0.0 (0.0 to 5.2)2.8 (0.3 to 9.8)1.5 (0.0 to 8.2)
SecondaryGroups 1, 2a, 2b, 2c, 3a and 3b: Percentage of Participants Who Achieved a PASI 75/90/100 Response at Weeks 20, 28, 68, 116, 164, and 220

Percentage of participants who achieved PASI 75/90/100 response were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease. PASI 75 responders were defined as participants with \>= 75% improvement in PASI from baseline. PASI 90 responders were defined as participants with \>= 90% improvement in PASI from baseline. PASI 100 responders were defined as participants with 100% improvement in PASI from baseline.

Time frame:
Group 1: Weeks 20, 28; Groups 2a, 2b, 2c: Week 68; Groups 3a, 3b: Weeks 116, 164 and 220
Reported as:
Number · Percentage of participants
Groups 1, 2a, 2b, 2c, 3a and 3b: Percentage of Participants Who Achieved a PASI 75/90/100 Response at Weeks 20, 28, 68, 116, 164, and 220
Percentage of participantsPart 1 Group 1: Guselkumab 100mgPart 2 Group 2a: Guselkumab 100 mg Q8WPart 2 Group 2b: Guselkumab 100 mg Q16WPart 2 Group 2c: Guselkumab 100 mg Q8WPart 3 Group 3a: Withdrawal (Q8W)Part 3 Group 3b: Withdrawal (Q16W)
PASI 75 (Week 20)90.2—————
PASI 75 (Week 28)90.7—————
PASI 90 (Week 20)73.6—————
PASI 90 (Week 28)76.0—————
PASI 100 (Week 20)39.4—————
PASI 100 (Week 28)44.4—————
PASI 75 (Week 68)—92.694.088.0——
PASI 90 (Week 68)—91.985.973.7——
PASI 100 (Week 68)—81.169.138.1——
PASI 75 (Week 116)————27.920.4
PASI 75 (Week 164)————10.38.0
PASI 75 (Week 220)————5.14.4
PASI 90 (Week 116)————18.413.1
PASI 90 (Week 164)————7.45.8
PASI 90 (Week 220)————5.12.9
PASI 100 (Week 116)————9.67.3
PASI 100 (Week 164)————5.92.9
PASI 100 (Week 220)————4.42.9
SecondaryGroup 3a and Group 3b: Time to Loss of Disease Control (Absolute PASI Score >5) After Treatment Withdrawal

Time to loss of disease control (absolute PASI score \>5) after treatment withdrawal beyond Week 68 up to Week 220 were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.

Time frame:
From Week 68 up to Week 220
Reported as:
Median · Days
Group 3a and Group 3b: Time to Loss of Disease Control (Absolute PASI Score >5) After Treatment Withdrawal
DaysPart 3 Group 3a: Withdrawal (Q8W)Part 3 Group 3b: Withdrawal (Q16W)
Group 3a and Group 3b: Time to Loss of Disease Control (Absolute PASI Score >5) After Treatment Withdrawal245 (203 to 286)189 (166 to 251)
SecondaryGroup 1: Percentage of Participants With an Absolute PASI Score = 0 at Weeks 12, 16, 20 and 28

Percentage of participants with an absolute PASI score = 0 at Weeks 12, 16, 20 and 28 were reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translated to numeric score that ranged from 0 (indicated no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.

Time frame:
Weeks 12, 16, 20 and 28
Reported as:
Number · Percentage of participants
Group 1: Percentage of Participants With an Absolute PASI Score = 0 at Weeks 12, 16, 20 and 28
Percentage of participantsPart 1 Group 1: Guselkumab 100 mg
Week 1217.8
Week 1629.0
Week 2039.4
Week 2844.4
SecondaryGroups 1, 2a, 2b, 2c, 3a, 3b and 3c: Change From Baseline (Week 0) in Dermatology Life Quality Index (DLQI) Score

Change from baseline (Week 0) in DLQI score were reported. DLQI was a 10-item instrument questionnaire designed to assess the impact of the disease on a participant's quality of life. Each question was evaluated on a 4-point scale ranged from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.

Time frame:
Group 1: Baseline (Week 0), Week 28; Group 2a, 2b, 2c: Baseline (Week 0), Week 68; Group 3a and Group 3b:Baseline (Week 0), Week 116, 164 and 220; Group 3c: Baseline (Re-Treatment [R] Week 0), Week R24
Reported as:
Mean · Score on scale
Groups 1, 2a, 2b, 2c, 3a, 3b and 3c: Change From Baseline (Week 0) in Dermatology Life Quality Index (DLQI) Score
Score on scalePart 1 Group 1: Guselkumab 100mgPart 2 Group 2a: Guselkumab 100 mg Q8WPart 2 Group 2b: Guselkumab 100 mg Q16WPart 2 Group 2c: Guselkumab 100 mg Q8WPart 3 Group 3a: Withdrawal (Q8W)Part 3 Group 3b: Withdrawal (Q16W)Part 3 Group 3c: Re-Treatment Guselkumab 100mg
Week 28-16.6 ± 6.2——————
Week 68—-18.8 ± 5.6-17.0 ± 5.5-17.1 ± 5.8———
Week 116————-16.5 ± 6.3-15.5 ± 6.4—
Week 164————-18.1 ± 6.7-17.4 ± 7.8—
Week 220————-20.9 ± 6.0-16.3 ± 6.5—
Re-Treatment till R24 weeks——————-10.1 ± 6.8
SecondaryGroups 1, 2a, 2b, 2c, 3a, 3b and 3c: Percentage of Participants Who Achieved a DLQI Score 0/1 and <5

Percentage of participants who achieved a DLQI score 0/1 and \<5 was reported. DLQI was a 10-item instrument questionnaire designed to assess the impact of the disease on a participant's quality of life. Each question was evaluated on a 4-point scale ranged from 0 (not at all) to 3 (very much); where higher scores indicated more impact on quality of life. Scores from all 10 questions added up to give DLQI total score ranged from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.

Time frame:
Group 1: Week 28; Groups 2a, 2b, 2c: Week 68; Groups 3a and 3b: Week 116, 164 and 220; Group 3c: Week R24
Reported as:
Number · Percentage of participants
Groups 1, 2a, 2b, 2c, 3a, 3b and 3c: Percentage of Participants Who Achieved a DLQI Score 0/1 and <5
Percentage of participantsPart 1 Group 1: Guselkumab 100mgPart 2 Group 2a: Guselkumab 100 mg Q8WPart 2 Group 2b: Guselkumab 100 mg Q16WPart 2 Group 2c: Guselkumab 100 mg Q8WPart 3 Group 3a: Withdrawal (Q8W)Part 3 Group 3b: Withdrawal (Q16W)Part 3 Group 3a: Participants With Disease Duration <=2 YearsPart 3 Group 3a: Participants With Disease Duration> 2 YearsPart 3 Group 3b: Participants With Disease Duration <= 2 YearsPart 3 Group 3b: Participants With Disease Duration > 2 YearsPart 3 Group 3c: Re-Treatment Guselkumab 100mg
DLQI Score 0/1 (Week 28)60.9——————————
DLQI Score<5 (Week 28)78.4——————————
DLQI Score 0/1 (Week 68)—83.177.961.9———————
DLQI Score<5 (Week 68)—89.285.278.9———————
DLQI Score 0/1 (Week 116)————15.410.9—————
DLQI Score <5 (Week 116)——————34.315.926.87.6—
DLQI Score 0/1 (Week 164)————8.15.8—————
DLQI Score <5 (Week 164)————8.18.0—————
DLQI Score 0/1 (Week 220)————4.42.9—————
DLQI Score <5 (Week 220)————5.14.4—————
DLQI Score 0/1 RT24——————————73.1
DLQI Score <5 RT24——————————87.7
SecondaryGroups 1, 2a, 2b, 2c, 3a, and 3b: Percent Change From Baseline (Week 0) in Psoriasis- Affected Body Surface Area (BSA)

Percent change from baseline in the psoriasis affected BSA (%) was reported. The percentage of the psoriasis-affected BSA percentage is a system used for assessing the severity of psoriasis. The plaque coverage is estimated using the rule of palm (1 palm of the hand = 1% BSA)

Time frame:
Group 1: Baseline (Week 0), Week 12, 28; Group 2a, 2b, 2c: Baseline (Week 0), Week 52 and 68, Group 3a, 3b: Baseline (Week 0), Week 80, 104, 116, 140, 164, 188, 212 and 220
Reported as:
Mean · Percent Change
Groups 1, 2a, 2b, 2c, 3a, and 3b: Percent Change From Baseline (Week 0) in Psoriasis- Affected Body Surface Area (BSA)
Percent ChangePart 1 Group 1: Guselkumab 100mgPart 2 Group 2a: Guselkumab 100 mg Q8WPart 2 Group 2b: Guselkumab 100 mg Q16WPart 2 Group 2c: Guselkumab 100 mg Q8WPart 3 Group 3a: Withdrawal (Q8W)Part 3 Group 3b: Withdrawal (Q16W)
At Week 12-19.3 ± 14.2—————
At Week 28-23.8 ± 15.0—————
At Week 52—-25.1 ± 15.1-24.3 ± 15.6-24.8 ± 14.6——
At Week 68—-24.8 ± 14.9-24.3 ± 15.8-25.0 ± 14.6——
At Week 80————-23.8 ± 14.1-23.6 ± 15.6
At Week 104————-20.6 ± 15.1-22.5 ± 16.8
At Week 116————-22.4 ± 16.8-19.8 ± 13.0
At Week 140————-16.7 ± 8.5-19.6 ± 11.2
At Week 164————-18.2 ± 8.7-20.6 ± 11.2
At Week 188————-18.1 ± 8.2-20.4 ± 13.0
At Week 212————-18.3 ± 9.6-19.3 ± 13.9
At Week 220————-18.3 ± 9.619.0 ± 13.6
SecondaryGroups 1, 2a, 2b, 2c, 3a and 3b: Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis- Clinical (NAPPA-CLIN) at Weeks 28, 68, 116, 164 and 220

Change from baseline in NAPPA-CLIN at Weeks 28, 68, 116 164, and 220 was reported. NAPPA-CLIN is an instrument used by the physician to assess the least and the worst involved nail of both hands or both feet with scores ranging from 0 (no involvement) to 16 (worst involvement). A higher score indicated a worst involvement.

Time frame:
Group 1: Baseline (Week 0), Week 28; Group 2a, 2b, 2c: Baseline (Week 0), Week 68; Group 3a and Group 3b: Baseline (Week 0), Week 116, 164, and 220
Reported as:
Mean · Score on scale
Groups 1, 2a, 2b, 2c, 3a and 3b: Change From Baseline in Nail Assessment in Psoriasis and Psoriatic Arthritis- Clinical (NAPPA-CLIN) at Weeks 28, 68, 116, 164 and 220
Score on scalePart 1 Group 1: Guselkumab 100mgPart 2 Group 2a: Guselkumab 100 mg Q8WPart 2 Group 2b: Guselkumab 100 mg Q16WPart 2 Group 2c: Guselkumab 100 mg Q8WPart 3 Group 3a: Withdrawal (Q8W)Part 3 Group 3b: Withdrawal (Q16W)
Hands (Week 28)-3.4 ± 3.2—————
Feet (Week 28)-3.1 ± 3.5—————
Hands (Week 68)—-4.0 ± 3.2-4.5 ± 3.5-4.0 ± 3.2——
Feet (Week 68)—-4.9 ± 3.5-4.6 ± 3.7-4.1 ± 3.6——
Hands (Week 116)————-2.2 ± 4.3-2.2 ± 3.2
Feet (Week 116)————-3.4 ± 6.2-3.5 ± 3.9
Hands (Week 164)————-4.5 ± 3.5-3.0 ± 2.4
Feet (Week 164)————-8.0 ± NA-3.6 ± 3.1
Hands (Week 220)————-4.3 ± 2.5-3.7 ± 2.5
Feet (Week 220)————-8.0 ± NA-4.0 ± 3.5
SecondaryGroups 1, 2a, 2b, 2c, 3a and 3b: Change From Baseline (Week 0) in the Signs and Symptoms Aggregate Scores of the Psoriasis Symptoms and Signs Diary (PSSD) at Weeks 28, 68, 116, 164 and 220

Change from baseline (Week 0) in the signs and symptoms aggregate scores of the PSSD at Weeks 28, 68, 116, 164 and 220 was reported. The PSSD was a questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a participant self-administered outcomes instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores each ranging from 0 to 100 were derived: the psoriasis symptom score and the psoriasis sign score. A higher score indicated more severe disease. A change of \>= 40 points in PSSD symptom score or sign score, and a \>= 3-point change in individual PSSD item scale scores was defined as clinically meaningful change (response).

Time frame:
Group 1: Baseline (Week 0), Week 28; Group 2a, 2b, 2c: Baseline (Week 0), Week 68; Group 3a and Group 3b: Baseline (Week 0), Week 116, 164, and 220
Reported as:
Mean · Score on scale
Groups 1, 2a, 2b, 2c, 3a and 3b: Change From Baseline (Week 0) in the Signs and Symptoms Aggregate Scores of the Psoriasis Symptoms and Signs Diary (PSSD) at Weeks 28, 68, 116, 164 and 220
Score on scalePart 1 Group 1: Guselkumab 100mgPart 2 Group 2a: Guselkumab 100 mg Q8WPart 2 Group 2b: Guselkumab 100 mg Q16WPart 2 Group 2c: Guselkumab 100 mg Q8WPart 3 Group 3a: Withdrawal (Q8W)Part 3 Group 3b: Withdrawal (Q16W)
At Week 28 (Symptom)-57.2 ± 25.4—————
At Week 28 (Sign)-62.1 ± 22.0—————
At Week 68 (Symptom)—-65.1 ± 21.2-58.7 ± 23.3-58.6 ± 25.1——
At Week 68 (Sign)—-71.7 ± 16.4-65.4 ± 19.6-63.0 ± 22.2——
At Week 116 (Symptom)————-52.3 ± 25.7-50.0 ± 24.3
At Week 116 (Sign)————-56.1 ± 25.6-52.2 ± 24.3
At Week 164 (Symptom)————-59.7 ± 20.5-54.0 ± 26.1
At Week 164 (Sign)————-62.1 ± 22.0-50.4 ± 26.5
At Week 220 (Symptom)————-56.0 ± 22.9-54.7 ± 23.1
At Week 220 (Sign)————-63.3 ± 20.3-54.7 ± 28.5
SecondaryGroups 2a, 2b and 2c: Percentage of Participants Who Achieved a PSSD Sign Score = 0 at Week 68 in Participants With a PSSD Sign Score >= 1 at Week 28

Percentage of participants who achieved a PSSD sign score = 0 at Week 68 in participants with a PSSD sign score \>= 1 at Week 28 was reported. The PSSD was a questionnaire designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. PSSD was a participant self-administered outcomes instrument that included 11 items covering symptoms (itch, pain, stinging, burning and skin tightness) and participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores each ranging from 0 to 100 were derived: the psoriasis symptom score and the psoriasis sign score. A higher score indicated more severe disease.

Time frame:
Week 68
Reported as:
Number · Percentage of participants
Groups 2a, 2b and 2c: Percentage of Participants Who Achieved a PSSD Sign Score = 0 at Week 68 in Participants With a PSSD Sign Score >= 1 at Week 28
Percentage of participantsPart 2 Group 2a: Guselkumab 100 mg Q8WPart 2 Group 2b: Guselkumab 100 mg Q16WPart 2 Group 2c: Guselkumab 100 mg Q8W
Groups 2a, 2b and 2c: Percentage of Participants Who Achieved a PSSD Sign Score = 0 at Week 68 in Participants With a PSSD Sign Score >= 1 at Week 2830.2 (22.1 to 39.4)21.7 (14.9 to 30.0)14.8 (12.1 to 17.8)
SecondaryGroups 2a and 2b: Serum Trough Guselkumab Levels at Weeks 20, 28, 36 and 68

Serum trough guselkumab levels at Weeks 20, 28, 36 were analyzed. Serum samples were analyzed to determine trough concentrations of guselkumab using a validated specific, and sensitive method. Week 28 data are presented in Part 2 arms (Groups 2a and 2b) as these groups were established at Week 28, however pre-Week 28 trough concentrations are also reported under these groups to assess potential differences between Part 1 PK characteristics.

Time frame:
At Weeks 20, 28, 36, 68
Reported as:
Mean · micrograms/mL
Groups 2a and 2b: Serum Trough Guselkumab Levels at Weeks 20, 28, 36 and 68
micrograms/mLPart 2 Group 2a: Guselkumab 100 mg Q8WPart 2 Group 2b: Guselkumab 100 mg Q16W
At Week 201.61 ± 0.9891.60 ± 1.049
At Week 281.58 ± 1.0101.67 ± 1.076
At Week 361.68 ± 1.0620.38 ± 0.396
At Week 681.56 ± 0.9600.31 ± 0.377
SecondaryGroups 2d and 3c: Percentage of Participants Who Were Re-Treated Due to Loss of Disease Control (PASI >5) and Regain Control of Disease (PASI <3) 24 Weeks After Start of Re-Treatment

Percentage of participants who were re-treated due to loss of disease control (PASI \>5) and regain control of disease (PASI \<3) 24 weeks after start of re-treatment was reported. PASI was a system used for assessing and grading severity of psoriatic lesions and their response to therapy. In PASI, body was divided into 4 regions: head, trunk, upper extremities, and lower extremities. Each of these areas was assessed separately for percentage of area involved, which translates to numeric score that ranged from 0 (indicates no involvement) to 6 (90%-100% involvement), and for erythema, induration, and scaling, which were each rated on a scale of 0 to 4. PASI produced a numeric score that could range from 0 (no psoriasis) to 72 (maximum psoriasis). Higher score indicated more severe disease.

Time frame:
Week R0 up to Week R24
Reported as:
Number · Percentage of participants
Groups 2d and 3c: Percentage of Participants Who Were Re-Treated Due to Loss of Disease Control (PASI >5) and Regain Control of Disease (PASI <3) 24 Weeks After Start of Re-Treatment
Percentage of participantsPart 2 Group 2d: Re-Treatment Guselkumab 100mgPart 3 Group 3c: Re-Treatment Guselkumab 100mg
Groups 2d and 3c: Percentage of Participants Who Were Re-Treated Due to Loss of Disease Control (PASI >5) and Regain Control of Disease (PASI <3) 24 Weeks After Start of Re-Treatment88.8 (29.2 to 100.0)98.2 (95.5 to 99.5)
SecondaryGroups 1, 2a, 2b, 2c, 2d,3a, 3b, and 3c: Percentage of Participants With Adverse Events as a Measure of Safety and Tolerability

An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.

Time frame:
Group 1: From Week 0 to Week 28; Group 2a,2b 2c: From Week 28 to Week 68; Group 3a, 3b: From Week 68 to Week 220; Group 2d, 3c: From Week R0 to Week R28
Reported as:
Number · Percentage of participants
Groups 1, 2a, 2b, 2c, 2d,3a, 3b, and 3c: Percentage of Participants With Adverse Events as a Measure of Safety and Tolerability
Percentage of participantsPart 1 Group 1: Guselkumab 100mgPart 2 Group 2a: Guselkumab 100 mg Q8WPart 2 Group 2b: Guselkumab 100 mg Q16WPart 2 Group 2c: Guselkumab 100 mg Q8WPart 2 Group 2d: Re-Treatment Guselkumab 100mgPart 3 Group 3a: Withdrawal (Q8W)Part 3 Group 3b: Withdrawal (Q16W)Part 3 Group 3c: Re-Treatment Guselkumab 100mg
From Week 0 to Week 2874.8———————
From Week 28 to Week 68—68.969.872.0————
Week 68 to Week 220—————55.155.5—
From Week R0 to Week R28————66.6——58.1
SecondaryGroups 1, 2a, 2b, 2c, 2d, 3a,3b and 3c: Number of Participants With Clinically Significant Laboratory Abnormalities

Number of participants with clinically significant laboratory abnormalities was reported. Data of participants with at least one lab abnormality is reported. Abnormality criteria: Aspartate Aminotransferase (AST) \>3, Alanine Aminotransferase (ALT).\>5. For arm 3a and 3b, no drug was administered, hence no laboratory data was collected, per planned analysis.

Time frame:
Group 1: Week 20, Group 2a, 2b,2c: Week 68 and Group 2d and 3c: Week R28
Reported as:
Count of participants · Participants
Groups 1, 2a, 2b, 2c, 2d, 3a,3b and 3c: Number of Participants With Clinically Significant Laboratory Abnormalities
ParticipantsPart 1 Group 1: Guselkumab 100mgPart 2 Group 2a: Guselkumab 100 mg Q8WPart 2 Group 2b: Guselkumab 100 mg Q16WPart 2 Group 2c: Guselkumab 100 mg Q8WPart 2 Group 2d: Re-Treatment Guselkumab 100mgPart 3 Group 3c: Re-Treatment Guselkumab 100mg
AST > 3 (Week 20)2—————
AST > 3 (Week 68)—1010—
ALT > 5 (Week 68)—1100—
AST > 3 (Week R28)—————0
ALT > 5 (Week R28)—————1

Adverse events

Collected over Group 1: All-cause mortality: From screening (Week -4) to Week 28; serious and other AEs: Week0 to Week 28; Groups 2a,2b,2c (all-cause mortality and SAEs/other AEs): Week 28 to Week 68; Groups 3a, 3b (all-cause mortality and SAEs/other AEs): Week 68 to Week 220; Groups 2d, 3c (all-cause mortality and SAEs/other AEs): Week R0 to Week R28. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 Group 1: Guselkumab 100mg1/880 (0.1%)38/880 (4.3%)631/880 (71.7%)
Group 2a: Guselkumab 100 mg Q8W0/148 (0%)7/148 (4.7%)101/148 (68.2%)
Group 2b: Guselkumab 100 mg Q16W0/150 (0%)6/149 (4%)103/149 (69.1%)
Group 2c: Guselkumab 100 mg Q8W1/525 (0.2%)33/525 (6.3%)367/525 (69.9%)
Part 2 Group 2d: Re-Treatment Guselkumab 100mg0/9 (0%)0/9 (0%)6/9 (66.7%)
Group 3a Guselkumab 100 mg Q8W0/136 (0%)3/136 (2.2%)75/136 (55.1%)
Group 3b Guselkumab 100 mg Q16W0/137 (0%)9/137 (6.6%)75/137 (54.7%)
Group 3c Guselkumab 100 mg0/227 (0%)8/227 (3.5%)130/227 (57.3%)
Most frequent serious events
Showing 10 of 94
Most frequent serious events
EventPart 1 Group 1: Guselkumab 100mgGroup 2a: Guselkumab 100 mg Q8WGroup 2b: Guselkumab 100 mg Q16WGroup 2c: Guselkumab 100 mg Q8WPart 2 Group 2d: Re-Treatment Guselkumab 100mgGroup 3a Guselkumab 100 mg Q8WGroup 3b Guselkumab 100 mg Q16WGroup 3c Guselkumab 100 mg
Ligament RuptureInjury, poisoning and procedural complications0/8800/1480/1491/5250/90/1362/1370/227
DepressionPsychiatric disorders1/8800/1480/1490/5250/90/1360/1372/227
Hiatus HerniaGastrointestinal disorders0/8800/1480/1490/5250/91/1360/1370/227
Ankle FractureInjury, poisoning and procedural complications1/8800/1480/1490/5250/91/1360/1371/227
SeromaInjury, poisoning and procedural complications0/8800/1480/1490/5250/91/1360/1370/227
PancreatitisGastrointestinal disorders0/8800/1480/1490/5250/90/1361/1370/227
Foot FractureInjury, poisoning and procedural complications1/8800/1480/1490/5250/90/1361/1370/227
Back PainMusculoskeletal and connective tissue disorders0/8800/1480/1490/5250/90/1361/1370/227
BursitisMusculoskeletal and connective tissue disorders1/8800/1480/1490/5250/90/1361/1370/227
CraniopharyngiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/8800/1480/1490/5250/90/1361/1370/227
Most frequent other events
Showing 10 of 652
Most frequent other events
EventPart 1 Group 1: Guselkumab 100mgGroup 2a: Guselkumab 100 mg Q8WGroup 2b: Guselkumab 100 mg Q16WGroup 2c: Guselkumab 100 mg Q8WPart 2 Group 2d: Re-Treatment Guselkumab 100mgGroup 3a Guselkumab 100 mg Q8WGroup 3b Guselkumab 100 mg Q16WGroup 3c Guselkumab 100 mg
NasopharyngitisInfections and infestations214/88026/14823/14997/5250/917/13617/13732/227
Nail psoriasisNervous system disorders0/8800/1480/1490/5252/90/1360/1370/227
Covid-19Infections and infestations10/8804/1483/14913/5251/920/13612/13721/227
Erythema MigransInfections and infestations0/8801/1480/1490/5251/90/1360/1370/227
Genital Infection FungalInfections and infestations1/8800/1480/1491/5251/90/1360/1370/227
Otitis MediaInfections and infestations1/8801/1480/1493/5251/90/1360/1370/227
Urinary Tract InfectionInfections and infestations8/8801/1483/1494/5251/91/1361/1371/227
Back PainMusculoskeletal and connective tissue disorders26/8806/1488/14913/5251/94/1362/1373/227
HeadacheNervous system disorders0/8800/1480/1490/5251/90/1360/1370/227
Pruritus genitalReproductive system and breast disorders0/8800/1480/1490/5251/90/1360/1370/227

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part 1 Group 1: Guselkumab 100 mg
<=18 years0
Between 18 and 65 years817
>=65 years63
Age, Continuous
Age, Continuous(years)Part 1 Group 1: Guselkumab 100 mg
Mean42.5 ± 14.7
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 Group 1: Guselkumab 100 mg
Female260
Male620
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1 Group 1: Guselkumab 100 mg
Asian8
Black1
White859
More than one race2
Unknown or Not Reported3
Other7
Region of Enrollment
Region of Enrollment(Participants)Part 1 Group 1: Guselkumab 100 mg
FRANCE52
GERMANY828
08

Study locations

90 sites
  • Hopital Prive d'Antony
    Antony, 92160, France
  • Centre Hospitalier d'Auxerre
    Auxerre, 89011, France
  • Polyclinique Reims Bezanne - De Courlancy
    Bezanne, 51430, France
  • Centre Hospitalier Le Mans
    Le Mans, 72037, France
  • Hôpital Edouard Herriot
    Lyon, 69437, France
  • Le Bateau Blanc
    Martigues, 13500, France
  • CHU Nantes
    Nantes, 44093, France
  • CHU de Nice Hopital de l Archet
    Nice, 06202, France
  • CHU Rouen
    Rouen, 76000, France
  • HIA se Sainte-Anne - Toulon
    Toulon, 83041, France
  • CHU Toulouse
    Toulouse, 31059, France
  • Universitätsklinikum Aachen
    Aachen, 52074, Germany
  • DermaManagement Augsburg GmbH
    Augsburg, 86179, Germany
  • Klinikum Augsburg
    Augsburg, 86179, Germany
  • Fachklinik Bad Bentheim
    Bad Bentheim, 48455, Germany
  • Hautmedizin Bad Soden
    Bad Soden am Taunus, 65812, Germany
  • Charite CCM, Dermatologie
    Berlin, 10117, Germany
  • Vivantes Klinikum Im Friedrichshain
    Berlin, 10119, Germany
  • Rothhaar Studien GmbH
    Berlin, 10783, Germany
  • ISA - Interdisciplinary Study Association GmbH
    Berlin, 10789, Germany
  • Hautarztpraxis
    Berlin, 12459, Germany
  • Hautarztpraxis Dr.Wildfeuer
    Berlin, 13055, Germany
  • Hautarztpraxis
    Berlin, 13597, Germany
  • Praxis 'Haut Pur'
    Berlin, 13597, Germany
  • Klinikum Bielefeld Rosenhoehe
    Bielefeld, 33647, Germany
  • Katholisches Klinikum Bochum gGmbH
    Bochum, 44791, Germany
  • Niesmann & Othlinghaus GbR
    Bochum, 44793, Germany
  • MVZ Dermatologisches Zentrum Bonn GmbH
    Bonn, 53111, Germany
  • Universitatsklinikum Bonn
    Bonn, 53127, Germany
  • Hautarztpraxis
    Borna, 04552, Germany
  • Hautarztpraxis
    Bramsche, 49565, Germany
  • Derma Nord
    Bremen, 28779, Germany
  • Universitaetsklinikum Koeln
    Cologne, 50937, Germany
  • Klinikum Darmstadt GmbH - Hautklinik
    Darmstadt, 64283, Germany
  • Rosenpark Research GmbH
    Darmstadt, 64283, Germany
  • Klinische Forschung Dresden GmbH
    Dresden, 01069, Germany
  • Praxis für Dermatologie und Venerologie
    Dresden, 01097, Germany
  • University Hospital Dresden
    Dresden, 01307, Germany
  • Pro Derma
    Dülmen, 48249, Germany
  • Privatpraxis Dr. Hilton & Partner
    Düsseldorf, 40212, Germany
  • Universitatsklinikum Dusseldorf
    Düsseldorf, 40225, Germany
  • Universitaetsklinik Erlangen
    Erlangen, 91054, Germany
  • Universitaetsklinikum Essen
    Essen, 45122, Germany
  • Universitatsklinikum Frankfurt
    Frankfurt am Main, 60590, Germany
  • Universitatsklinikum Freiburg
    Freiburg im Breisgau, 79104, Germany
  • Derma-Study-Center Friedrichshafen GmbH
    Friedrichshafen, 88045, Germany
  • SRH Waldklinikum Gera GmbH
    Gera, 07548, Germany
  • Hautarztpraxis Brau/Groß
    Giessen, 35390, Germany
  • Universitatsmedizin Gottingen
    Göttingen, 37075, Germany
  • Universitaetsklinik Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Klinische Forschung Hamburg
    Hamburg, 20253, Germany
  • Dermatologikum Hamburg Gmbh
    Hamburg, 20354, Germany
  • SCIderm GmbH
    Hamburg, 20537, Germany
  • MensingDerma research GmbH
    Hamburg, 22391, Germany
  • Die Hautklinik Hanau
    Hanau, 63450, Germany
  • Haut- und Laserzentrum Heidelberg
    Heidelberg, 69115, Germany
  • Universitaetsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Hautarztpraxis Offers/Adamini
    Ibbenbueren, 49477, Germany
  • Universitatsklinikum Jena
    Jena, 07745, Germany
  • Universitatsklinikum Schleswig Holstein Kiel
    Kiel, 24105, Germany
  • MVZ DermaKiel GmbH
    Kiel, 24148, Germany
  • Praxis Dr. med. Beate Schwarz - Germany
    Langenau, 89129, Germany
  • Universitatsklinikum Leipzig AOR
    Leipzig, 04103, Germany
  • Hautarztpraxis
    Lingen, 49809, Germany
  • Otto Von Guericke Universität Magdeburg
    Magdeburg, 39120, Germany
  • Gemeinschaftspraxis Scholz/Sebastian/Schilling
    Mahlow, 15831, Germany
  • Hautarztzentrum am MDZ
    Mainz, 55128, Germany
  • Universitaetsmedizin Mainz
    Mainz, 55131, Germany
  • Universitaetsklinikum Mannheim
    Mannheim, 68167, Germany
  • Hautarztpraxis
    Memmingen, 87700, Germany
  • Zentderma BAG Dres. Ostendorf - Bohm - Jo GbR
    Mönchengladbach, 41061, Germany
  • Technische Universitaet Muenchen
    München, 80802, Germany
  • Universitaetsklinikum Muenster
    Münster, 48149, Germany
  • Klinikum Oldenburg
    Oldenburg, 26133, Germany
  • Klinische Forschung Osnabrück
    Osnabrück, 49074, Germany
  • Hautarztpraxis
    Potsdam, 14467, Germany
  • Harzklinikum Dorothea Christiane Erxleben GmbH - Germnay
    Quedlinburg, 06484, Germany
  • Universitaetsklinikum Regensburg
    Regensburg, 93053, Germany
  • Hautarztpraxis Mortazawi
    Remscheid, 42897, Germany
  • Klinische Forschung Schwerin GmbH
    Schwerin, 19055, Germany
  • Company for Medical Study & Service Selters
    Selters, 56242, Germany
  • Hautarztpraxis Dr. Leitz & Kollegen
    Stuttgart, 70178, Germany
  • Hautarztpraxis am Loewenmarkt
    Stuttgart, 70499, Germany
  • Universitatsklinikum Tubingen
    Tübingen, 72076, Germany
  • Universitatsklinikum Ulm
    Ulm, 89081, Germany
  • Hautarztpraxis Kock
    Vechta, 49377, Germany
  • Centrovital
    Witten, 58453, Germany
  • HELIOS Klinikum Wuppertal GmbH
    Wuppertal, 42283, Germany
  • CentroDerm GmbH
    Wuppertal, 42287, Germany
  • Universitatsklinikum Wurzburg
    Würzburg, 97080, Germany
09

References and documents

Publications

  • Eyerich K, Asadullah K, Pinter A, Weisenseel P, Reich K, Paul C, Sabat R, Wolk K, Eyerich S, Lauffer F, Angsana J, Taut FJH, Kohler K, Chen Y, Sendecki J, Leung MWL, Wegner S, Personke Y, Gomez M, Kruger N, Tabori S, Schakel K. Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial. JAMA Dermatol. 2024 Sep 1;160(9):953-963. doi: 10.1001/jamadermatol.2024.2463. PubMed 39083288 ↗
  • Eyerich K, Weisenseel P, Pinter A, Schakel K, Asadullah K, Wegner S, Munoz-Elias EJ, Bartz H, Taut FJH, Reich K. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). BMJ Open. 2021 Sep 13;11(9):e049822. doi: 10.1136/bmjopen-2021-049822. PubMed 34518264 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Mar 2022, 36 months.

Results were first posted in May 2023, 1 year 2 months after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 36 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2019
First posted
Jan 28, 2019
StartActual
Feb 8, 2019
Primary completionActual
Mar 7, 2022
CompletionActual
Jan 7, 2025
Results first posted
May 10, 2023
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03818035
Responsible party
Sponsor
First posted
Jan 28, 2019
Start date
Feb 8, 2019
Primary completion
Mar 7, 2022
Completion
Jan 7, 2025
Results posted
May 10, 2023
Last update
Jan 23, 2026

Study contacts

Janssen-Cilag International NV Clinical Trial
study director · Janssen-Cilag International NV

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion